Attached files

file filename
8-K - 8-K - ABBOTT LABORATORIESa17-2745_18k.htm

Exhibit 99.1

 

Abbott Laboratories

Cardiovascular and Neuromodulation

2016 Comparable Sales*

(unaudited)

 

Worldwide

 

 

 

2016 Sales ($ in millions)

 

 

 

1Q

 

2Q

 

3Q

 

3Q YTD

 

Rhythm Management and Heart Failure

 

1,021

 

1,089

 

1,034

 

3,144

 

Cardiovascular and Structural Heart

 

921

 

1,037

 

958

 

2,916

 

Neuromodulation

 

116

 

140

 

141

 

397

 

Total Cardiovascular and Neuromodulation

 

2,058

 

2,266

 

2,133

 

6,457

 

 

U.S.

 

 

 

2016 Sales ($ in millions)

 

 

 

1Q

 

2Q

 

3Q

 

3Q YTD

 

Rhythm Management and Heart Failure

 

570

 

574

 

551

 

1,695

 

Cardiovascular and Structural Heart

 

368

 

427

 

390

 

1,185

 

Neuromodulation

 

84

 

97

 

106

 

287

 

Total Cardiovascular and Neuromodulation

 

1,022

 

1,098

 

1,047

 

3,167

 

 

International

 

 

 

2016 Sales ($ in millions)

 

 

 

1Q

 

2Q

 

3Q

 

3Q YTD

 

Rhythm Management and Heart Failure

 

451

 

515

 

483

 

1,449

 

Cardiovascular and Structural Heart

 

553

 

610

 

568

 

1,731

 

Neuromodulation

 

32

 

43

 

35

 

110

 

Total Cardiovascular and Neuromodulation

 

1,036

 

1,168

 

1,086

 

3,290

 

 


*Abbott’s cardiovascular and neuromodulation (ACN) business includes Abbott’s historical Vascular Products segment and the businesses of St. Jude Medical, LLC. St. Jude Medical’s vascular closure business has been removed from all periods presented above given the recent divestiture of this business. Administrative fees paid by St. Jude Medical to group purchasing organizations have been reclassified from the Selling, general and administrative line in St. Jude Medical’s historical financial statements and are included as a reduction to revenue to conform to Abbott’s presentation. Abbott completed its acquisition of St. Jude Medical, Inc. (now St. Jude Medical, LLC) on January 4, 2017.